[go: up one dir, main page]

BE2011C041I2 - - Google Patents

Download PDF

Info

Publication number
BE2011C041I2
BE2011C041I2 BE2011C041C BE2011C041C BE2011C041I2 BE 2011C041 I2 BE2011C041 I2 BE 2011C041I2 BE 2011C041 C BE2011C041 C BE 2011C041C BE 2011C041 C BE2011C041 C BE 2011C041C BE 2011C041 I2 BE2011C041 I2 BE 2011C041I2
Authority
BE
Belgium
Application number
BE2011C041C
Original Assignee
Bristol-Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Co filed Critical Bristol-Myers Squibb Co
Publication of BE2011C041I2 publication Critical patent/BE2011C041I2/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BE2011C041C 2000-05-26 2011-11-10 BE2011C041I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57992700A 2000-05-26 2000-05-26
US21406500P 2000-06-26 2000-06-26
PCT/US2001/017139 WO2001092337A2 (fr) 2000-05-26 2001-05-23 Molecules ctla4 mutantes solubles et leurs utilisations

Publications (1)

Publication Number Publication Date
BE2011C041I2 true BE2011C041I2 (fr) 2020-08-20

Family

ID=26908652

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2011C041C BE2011C041I2 (fr) 2000-05-26 2011-11-10

Country Status (41)

Country Link
EP (3) EP3029062A1 (fr)
JP (1) JP4328525B2 (fr)
KR (2) KR100889887B1 (fr)
CN (2) CN101255192A (fr)
AR (1) AR031699A1 (fr)
AT (1) ATE271066T1 (fr)
AU (2) AU2001263466C1 (fr)
BE (1) BE2011C041I2 (fr)
BR (1) BRPI0111191B8 (fr)
CA (1) CA2409748C (fr)
CY (2) CY2011019I2 (fr)
CZ (1) CZ304451B6 (fr)
DE (2) DE60104282T2 (fr)
DK (1) DK1248802T3 (fr)
EC (1) ECSP024365A (fr)
EE (2) EE05458B1 (fr)
EG (1) EG24459A (fr)
ES (2) ES2225549T3 (fr)
FR (1) FR11C0053I2 (fr)
GE (1) GEP20053658B (fr)
HK (1) HK1048126B (fr)
HU (2) HU228137B1 (fr)
IL (1) IL152315A (fr)
LT (1) LT5133B (fr)
LU (1) LU91902I2 (fr)
LV (1) LV12994B (fr)
MX (1) MXPA02011534A (fr)
MY (1) MY136113A (fr)
NO (2) NO330797B1 (fr)
PE (1) PE20011338A1 (fr)
PL (1) PL206267B1 (fr)
PT (1) PT1248802E (fr)
RU (1) RU2283847C2 (fr)
SI (1) SI1248802T1 (fr)
SK (1) SK288131B6 (fr)
TR (1) TR200402703T4 (fr)
TW (2) TWI319405B (fr)
UA (1) UA87432C2 (fr)
UY (1) UY26723A1 (fr)
WO (1) WO2001092337A2 (fr)
ZA (1) ZA200208944B (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887471B1 (en) 1991-06-27 2005-05-03 Bristol-Myers Squibb Company Method to inhibit T cell interactions with soluble B7
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
CZ303959B6 (cs) * 2000-07-03 2013-07-17 Bristol-Myers Squibb Company Solubilní CTLA4 fúzní molekula, farmaceutický prostredek s jejím obsahem a její pouzití
US20040022787A1 (en) 2000-07-03 2004-02-05 Robert Cohen Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID
DK1397153T3 (da) 2001-05-23 2008-05-26 Bristol Myers Squibb Co Fremgangsmåde til beskyttelse af allogent ö-celle-transplantat ved anvendelse af oplöselige CTLA4-mutantmolekyler
EP1496931A4 (fr) * 2002-04-19 2009-07-01 Bristol Myers Squibb Co Methodes de traitement d'une maladie auto-immune au moyen d'une molecule ctla4 soluble et d'un armm ou d'un ains
DE10232697A1 (de) * 2002-07-15 2004-02-05 Universitätsklinikum Charité, Medizinische Fakultät der Humboldt-Universität zu Berlin Verwendung von CD152 zur Behandlung von Autoimmunkrankheiten und Entzündungen
ES2354610T5 (es) 2002-12-23 2020-09-14 Bristol Myers Squibb Co Mejora de la calidad del producto en procedimientos de cultivo de células de mamífero para la producción de proteína
AU2003300276B2 (en) 2002-12-23 2010-07-01 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
JP2006517191A (ja) 2002-12-30 2006-07-20 アムジエン・インコーポレーテツド 共刺激因子を用いた併用療法
CA2543484C (fr) 2003-10-27 2014-02-04 Amgen Inc. Modulation de reponse immunitaire a un immunogene avec le ctla-4 et une proteine de liaison du facteur de necrose de tumeur
PT1969007E (pt) * 2005-12-20 2013-12-10 Bristol Myers Squibb Co Composições e métodos para a produção de uma composição
AR058568A1 (es) 2005-12-20 2008-02-13 Bristol Myers Squibb Co Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo
US7510844B2 (en) 2006-01-24 2009-03-31 Bristol-Myers Squibb Company CD86 and CD80 receptor competition assays
WO2008005290A2 (fr) 2006-06-29 2008-01-10 The Trustees Of Columbia University In The City Of New York Procédés de test d'agents anti-thrombotiques
GB0620934D0 (en) 2006-10-20 2006-11-29 Cambridge Antibody Tech Protein variants
WO2008076487A2 (fr) 2006-12-20 2008-06-26 Verenium Corporation Anticorps: procédé de fabrication et d'utilisation
CN103172750B (zh) 2007-11-01 2014-12-10 安斯泰来制药有限公司 免疫抑制性多肽与核酸
KR20170091801A (ko) * 2008-10-02 2017-08-09 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Ｃｄ86 길항제 다중-표적 결합 단백질
US9540426B2 (en) * 2009-10-06 2017-01-10 Bristol-Myers Squibb Company Mammalian cell culture processes for protein production
WO2011113019A2 (fr) * 2010-03-12 2011-09-15 Abbott Biotherapeutics Corp. Protéines ctla4 et leurs utilisations
JP2014506482A (ja) 2011-02-23 2014-03-17 アムジエン・インコーポレーテツド Ｕｖｃ露光のための細胞培養培地およびそれに関連した方法
WO2013010537A1 (fr) 2011-07-20 2013-01-24 Aarhus Universitet Procédé de traitement de la morphée
WO2013148049A1 (fr) * 2012-03-29 2013-10-03 The General Hospital Corporation Protéine 4 associée aux lymphocytes t cytotoxiques (ctla4) recombinant
AU2013260172B2 (en) * 2012-05-11 2017-11-23 Medimmune Limited CTLA-4 variants
US8735359B2 (en) 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
CN104519900A (zh) 2012-06-27 2015-04-15 欧尔本生物科技有限责任公司 用于治疗糖尿病的ctla4融合蛋白
US20140112958A1 (en) 2012-10-24 2014-04-24 Mwm Biomodels Gmbh Pancreatic islets of transgenic LEA29Y animals for treating diabetes
CN104740608A (zh) * 2013-12-30 2015-07-01 上海中信国健药业股份有限公司 可溶性ctla4分子用于制备治疗类风湿性关节炎药物的用途
JP6732660B2 (ja) 2014-01-13 2020-07-29 アムジエン・インコーポレーテツド 組換えタンパク質の高マンノースグリコフォーム含有量を操作するためのオルニチン代謝の調節
GB2523399B (en) 2014-02-25 2019-03-13 Orban Tihamer A composition comprising ten overlapping peptide fragments of the entire preproinsulin sequence
HUE042277T2 (hu) 2014-06-04 2019-06-28 Amgen Inc Eljárások fehérjék begyûjtésére emlõssejttenyészetekbõl
LT3227454T (lt) 2014-12-01 2020-07-27 Amgen Inc. Glikoproteino glikano sudedamosios dalies kiekio keitimo procedūra
WO2016130734A1 (fr) 2015-02-11 2016-08-18 Bristol-Myers Squibb Company Utilisation d'antioxydants phénoliques dans la culture cellulaire pour la production de protéines
PT3283508T (pt) 2015-04-17 2021-06-21 Alpine Immune Sciences Inc Proteínas imuno modulatórias com afinidades afináveis
EP3347486A4 (fr) 2015-09-09 2019-06-19 The Trustees of Columbia University in the City of New York Réduction du fragment c99 de l'app localisé sur la membrane er-mam et procédés de traitement de la maladie d'alzheimer
JP2018536404A (ja) 2015-11-09 2018-12-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃｈｏ細胞において産生したポリペプチドの品質特性を操作する方法
EP3515489B1 (fr) * 2016-09-19 2025-11-05 OncoC4, Inc. Compositions de protéine de liaison à cd80 et cd86 et leurs utilisations
CN107987153A (zh) * 2016-10-27 2018-05-04 广东香雪精准医疗技术有限公司 高亲和力的可溶性pd-1分子
BR112019021977A2 (pt) 2017-04-20 2020-06-16 Egenesis, Inc. Métodos para a geração de animais geneticamente modificados
MA50360A (fr) * 2017-10-10 2020-08-19 Alpine Immune Sciences Inc Protéines immunomodulatrices de variants de ctla-4 et leurs utilisations
EP3735417A1 (fr) 2018-01-03 2020-11-11 Alpine Immune Sciences, Inc. Protéines immunomodulatrices multi-domaine et leurs méthodes d'utilisation
CN115227824A (zh) * 2018-11-12 2022-10-25 中南大学湘雅二医院 免疫检查点的抑制剂在制备治疗青光眼和其他眼部免疫损伤机制相关疾病药物中的应用
CN115551530A (zh) 2019-08-27 2022-12-30 通尼克斯制药有限公司 经修饰的tff2多肽
AU2020398125C1 (en) 2019-12-06 2023-05-11 Regeneron Pharmaceuticals, Inc. Anti-VEGF protein compositions and methods for producing the same
AU2021268026A1 (en) 2020-05-08 2023-01-19 Regeneron Pharmaceuticals, Inc. VEGF traps and mini-traps and methods for treating ocular disorders and cancer
US12123879B2 (en) 2020-06-18 2024-10-22 Regeneron Pharmaceuticals, Inc. Heavy peptide approach to accurately measure unprocessed C-terminal lysine
JP2023537670A (ja) 2020-07-28 2023-09-05 シージェン インコーポレイテッド ポリペプチドを生産するための方法及びシステム
US20250040546A1 (en) 2021-12-16 2025-02-06 Bristol-Myers Squibb Company Detergent for viral inactivation
AU2023229164A1 (en) 2022-03-02 2024-09-12 Regeneron Pharmaceuticals, Inc. Cell culture methods for antibody production

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
CA2110518C (fr) * 1991-06-27 2007-05-22 Peter S. Linsley Recepteur ctla4, proteines de fusion contenant ce recepteur et utilisations de ces dernieres
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
US5851795A (en) 1991-06-27 1998-12-22 Bristol-Myers Squibb Company Soluble CTLA4 molecules and uses thereof
ZA98533B (en) * 1997-01-31 1999-07-22 Bristol Myers Squibb Co Soluble CTLA4 mutant molecules and uses thereof.
JP3521382B2 (ja) * 1997-02-27 2004-04-19 日本たばこ産業株式会社 細胞間接着及びシグナル伝達を媒介する細胞表面分子
GB9809280D0 (en) * 1998-04-30 1998-07-01 Rpms Technology Ltd Immunosupression
WO2000019988A1 (fr) * 1998-10-07 2000-04-13 Millennium Pharmaceuticals, Inc. NOUVELLES MOLECULES SPECIFIQUES DE Th2 ET LEURS UTILISATIONS
CZ303959B6 (cs) * 2000-07-03 2013-07-17 Bristol-Myers Squibb Company Solubilní CTLA4 fúzní molekula, farmaceutický prostredek s jejím obsahem a její pouzití

Also Published As

Publication number Publication date
EE200200659A (et) 2004-06-15
EP1536234B1 (fr) 2016-03-16
HUP0302201A2 (hu) 2003-10-28
ES2225549T3 (es) 2005-03-16
CA2409748A1 (fr) 2001-12-06
EP3029062A1 (fr) 2016-06-08
WO2001092337A2 (fr) 2001-12-06
HUS1300012I1 (hu) 2016-08-29
EP1536234A2 (fr) 2005-06-01
NO2011027I1 (no) 2012-01-09
CY2011019I1 (el) 2016-12-14
AU2001263466C1 (en) 2006-10-26
CN101255192A (zh) 2008-09-03
KR20070094019A (ko) 2007-09-19
LU91902I2 (fr) 2012-01-16
SK15702002A3 (sk) 2004-01-08
DE60104282D1 (de) 2004-08-19
CA2409748C (fr) 2008-09-16
ATE271066T1 (de) 2004-07-15
UY26723A1 (es) 2001-12-28
CN1309735C (zh) 2007-04-11
AR031699A1 (es) 2003-10-01
EE201100050A (et) 2011-10-17
CY1117625T1 (el) 2017-04-26
BRPI0111191B8 (pt) 2021-05-25
TR200402703T4 (tr) 2004-11-22
CZ304451B6 (cs) 2014-05-14
PL366231A1 (en) 2005-01-24
MY136113A (en) 2008-08-29
EP1248802B1 (fr) 2004-07-14
TW200906857A (en) 2009-02-16
EG24459A (en) 2009-07-16
RU2283847C2 (ru) 2006-09-20
DE122011100063I1 (de) 2012-06-14
IL152315A (en) 2010-04-15
PT1248802E (pt) 2004-11-30
CY2011019I2 (el) 2016-12-14
EP1248802A2 (fr) 2002-10-16
NO330797B1 (no) 2011-07-18
HK1071931A1 (en) 2005-08-05
IL152315A0 (en) 2003-05-29
GEP20053658B (en) 2005-11-10
HK1048126A1 (en) 2003-03-21
ES2571852T3 (es) 2016-05-27
HUP0302201A3 (en) 2010-01-28
JP2004511213A (ja) 2004-04-15
EE05557B1 (et) 2012-08-15
ZA200208944B (en) 2004-02-13
HK1048126B (en) 2005-03-04
DK1248802T3 (da) 2004-11-15
SK288131B6 (sk) 2013-10-02
WO2001092337A3 (fr) 2002-05-10
CN1441810A (zh) 2003-09-10
EP1536234A3 (fr) 2009-06-03
NO20025656L (no) 2002-11-25
KR100889887B1 (ko) 2009-03-24
JP4328525B2 (ja) 2009-09-09
TWI319405B (en) 2010-01-11
FR11C0053I1 (fr) 2012-01-13
ECSP024365A (es) 2003-03-31
FR11C0053I2 (fr) 2013-01-11
EE05458B1 (et) 2011-08-15
AU2001263466B2 (en) 2006-04-27
SI1248802T1 (en) 2005-02-28
NO20025656D0 (no) 2002-11-25
EP1248802B9 (fr) 2005-05-11
CZ20023892A3 (cs) 2003-09-17
LV12994B (en) 2003-08-20
PE20011338A1 (es) 2002-01-13
PL206267B1 (pl) 2010-07-30
UA87432C2 (uk) 2009-07-27
KR20030009502A (ko) 2003-01-29
MXPA02011534A (es) 2004-08-12
LT5133B (lt) 2004-05-25
NO2011027I2 (fr) 2011-12-15
DE60104282T2 (de) 2005-10-13
AU6346601A (en) 2001-12-11
BR0111191A (pt) 2004-07-06
LT2002114A (en) 2003-12-29
TWI314933B (en) 2009-09-21
HU228137B1 (en) 2012-12-28
BRPI0111191B1 (pt) 2019-12-31
KR100895134B1 (ko) 2009-05-04

Similar Documents

Publication Publication Date Title
BE2017C009I2 (fr)
BE2016C018I2 (fr)
BE2014C019I2 (fr)
BE2013C060I2 (fr)
BE2013C048I2 (fr)
BE2012C016I2 (fr)
BRPI0113420B8 (fr)
BRPI0113085B8 (fr)
FR11C0053I1 (fr)
BE2010C040I2 (fr)
BRPI0113372A8 (fr)
BR0112866A2 (fr)
AU2000280296A8 (fr)
CN3137472S (fr)
CN3144126S (fr)
AU2000278679A8 (fr)
AU2000278563A8 (fr)
AU2000276780A8 (fr)
AU2000271150A8 (fr)
AU2000270908A8 (fr)
AU2000266391A8 (fr)
AU2000264849A8 (fr)
AU2000256695A8 (fr)
AU2000256023A8 (fr)
CN3133951S (fr)